ATYR aTYR PHARMA INC
Price Chart
Executive Summary
aTyr Pharma received a Nasdaq deficiency notice on December 4, 2025 for failing to maintain a minimum $1.00 bid price. On June 3, 2026, Nasdaq granted an additional 180-day compliance period through November 30, 2026, contingent on the company meeting other listing standards and its intent to cure via a reverse stock split if needed. Failure to regain compliance by the deadline could lead to delisting, which would severely reduce institutional ownership and liquidity.
Actionable Insight
Monitor the stock price for any sustained move above $1.00; a reverse stock split is the most likely cure but may be viewed negatively by the market. If the stock fails to recover by late November 2026, delisting risk becomes acute. The recent insider buy of $50K provides a modest positive signal but does not offset the structural risk.
Key Facts
- Nasdaq bid price deficiency notice received December 4, 2025; initial 180-day compliance period ended June 2, 2026.
- Nasdaq granted a second 180-day compliance period through November 30, 2026.
- Company intends to cure by effecting a reverse stock split if necessary.
- If compliance is not regained by November 30, 2026, Nasdaq will initiate delisting proceedings.
- Market cap is approximately $46M; stock is trading below $1.00 per share.
- One insider purchased $50K of stock in the last 30 days.
Financial Impact
No specific financial figures provided; delisting risk is material for a $46M market cap company.
Risk Factors
- Failure to regain compliance by November 30, 2026 could lead to Nasdaq delisting.
- Reverse stock split may be necessary but can be perceived as a sign of distress.
- Low market cap and sub-$1.00 price limit institutional ownership and liquidity.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001339970-26-000039 |
| Document: 0001339970-26-000039-index-headers.html | 0001339970-26-000039 |
| Document: 0001339970-26-000039-index.html | 0001339970-26-000039 |
| Document: 0001339970-26-000039.txt | 0001339970-26-000039 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
1d ago
|
8-K
| $0.4430 awaiting T+1 | awaiting T+1 | — | $0.4620 (−4.29%) |
|
Jun 1, 2026
8d ago
|
8-K
| $0.5200 $0.5001 | ▼ −3.83% | ▼ −3.13% | $0.4620 (−11.15%) |
|
May 15, 2026
26d ago
|
8-K
| $0.5040 $0.5200 | ▲ +3.17% | ▲ +3.24% | $0.4620 (−8.33%) |
|
May 15, 2026
26d ago
|
Press Release
| $0.5040 $0.5200 | ▲ +3.17% | ▲ +3.24% | $0.4620 (−8.33%) |
|
May 11, 2026
29d ago
|
8-K
| $0.5300 $0.5300 | · 0.00% | ▼ −0.54% | $0.4620 (−12.83%) |
|
Mar 26, 2026
10w ago
|
DEFA14A
| $0.7520 $0.7310 | ▼ −2.79% | ▼ −2.43% | $0.4620 (−38.56%) |
|
Mar 5, 2026
13w ago
|
8-K
| $0.8240 $0.9000 | ▲ +9.22% | ▲ +8.38% | $0.4620 (−43.93%) |
|
Mar 5, 2026
13w ago
|
Press Release
| $0.8240 $0.9000 | ▲ +9.22% | ▲ +8.38% | $0.4620 (−43.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access